Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Carmichael

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancerTomasz Burzykowski, Marc Buyse, Martine J Piccart-Gebhart, et al.
International Journal of Cancer|November 23, 2024
Calcium sensing receptor expression is downregulated in gastroenteropancreatic neuroendocrine tumours via epigenetic mechanismsKatherine A English, Michelle Goldsworthy, Brittannie Willis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerStan B Kaye, Jan Lubinski, Ursula Matulonis, et al.
Science Advances|March 22, 2024
<i>SF3B1</i> mutations provide genetic vulnerability to copper ionophores in human acute myeloid leukemiaCéline Moison, Deanne Gracias, Julie Schmitt, et al.
The New England Journal of Medicine|June 26, 2009
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersPeter C Fong, David S Boss, Timothy A Yap, et al.
Journal of Medicinal Chemistry|April 21, 2017
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and AiolosMary E Matyskiela, Weihong Zhang, Hon-Wah Man, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotypeCharlie Gourley, Caroline O Michie, Patricia Roxburgh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalPeter C Fong, Timothy A Yap, David S Boss, et al.
Haematologica|January 14, 2017
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana LinfomiFrancesco Zaja, Simone Ferrero, Caterina Stelitano, et al.
Nature|June 25, 2016
A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligaseMary E Matyskiela, Gang Lu, Takumi Ito, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancerTomasz Burzykowski, Marc Buyse, Martine J Piccart-Gebhart, et al.
International Journal of Cancer|November 23, 2024
Calcium sensing receptor expression is downregulated in gastroenteropancreatic neuroendocrine tumours via epigenetic mechanismsKatherine A English, Michelle Goldsworthy, Brittannie Willis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerStan B Kaye, Jan Lubinski, Ursula Matulonis, et al.
Science Advances|March 22, 2024
<i>SF3B1</i> mutations provide genetic vulnerability to copper ionophores in human acute myeloid leukemiaCéline Moison, Deanne Gracias, Julie Schmitt, et al.
The New England Journal of Medicine|June 26, 2009
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersPeter C Fong, David S Boss, Timothy A Yap, et al.
Journal of Medicinal Chemistry|April 21, 2017
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and AiolosMary E Matyskiela, Weihong Zhang, Hon-Wah Man, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotypeCharlie Gourley, Caroline O Michie, Patricia Roxburgh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalPeter C Fong, Timothy A Yap, David S Boss, et al.
Haematologica|January 14, 2017
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana LinfomiFrancesco Zaja, Simone Ferrero, Caterina Stelitano, et al.
Nature|June 25, 2016
A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligaseMary E Matyskiela, Gang Lu, Takumi Ito, et al.
Pageof 7